Search research articles
Contact Us
Filters
Showing results (61-70 of 79) with videos related to
Page
of 8
Sort By:
The Lancet. Oncology
|
June 9, 2017
Dabrafenib plus trametinib in patients with BRAF<sup>V600</sup>-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Michael A Davies, Philippe Saiag, Caroline Robert, et al.
Melanoma Research
|
November 25, 2020
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)
F Stephen Hodi, Paul B Chapman, Mario Sznol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 16, 2017
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
Mario Sznol, Pier Francesco Ferrucci, David Hogg, et al.
Familial Cancer
|
July 18, 2009
Younger age-at-diagnosis for familial malignant testicular germ cell tumor
Phuong L Mai, Bingshu E Chen, Kathy Tucker, et al.
The Lancet. Oncology
|
March 13, 2017
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer, Dirk Schadendorf, Paolo A Ascierto, et al.
Cancer
|
January 9, 2020
Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs
Aaron R Hansen, Kari Ala-Leppilampi, Chris McKillop, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 9, 2008
A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL)
Mark Harland, Alisa M Goldstein, Kairen Kukalizch, et al.
The Lancet. Oncology
|
February 11, 2014
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
Grant A McArthur, Paul B Chapman, Caroline Robert, et al.
The New England Journal of Medicine
|
June 7, 2011
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Paul B Chapman, Axel Hauschild, Caroline Robert, et al.
The New England Journal of Medicine
|
September 29, 2019
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 79) with videos related to
Sort By:
Page
of 8
The Lancet. Oncology
|
June 9, 2017
Dabrafenib plus trametinib in patients with BRAF<sup>V600</sup>-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Michael A Davies, Philippe Saiag, Caroline Robert, et al.
Melanoma Research
|
November 25, 2020
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)
F Stephen Hodi, Paul B Chapman, Mario Sznol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 16, 2017
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
Mario Sznol, Pier Francesco Ferrucci, David Hogg, et al.
Familial Cancer
|
July 18, 2009
Younger age-at-diagnosis for familial malignant testicular germ cell tumor
Phuong L Mai, Bingshu E Chen, Kathy Tucker, et al.
The Lancet. Oncology
|
March 13, 2017
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer, Dirk Schadendorf, Paolo A Ascierto, et al.
Cancer
|
January 9, 2020
Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs
Aaron R Hansen, Kari Ala-Leppilampi, Chris McKillop, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 9, 2008
A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL)
Mark Harland, Alisa M Goldstein, Kairen Kukalizch, et al.
The Lancet. Oncology
|
February 11, 2014
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
Grant A McArthur, Paul B Chapman, Caroline Robert, et al.
The New England Journal of Medicine
|
June 7, 2011
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Paul B Chapman, Axel Hauschild, Caroline Robert, et al.
The New England Journal of Medicine
|
September 29, 2019
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Page
of 8